A meta-analysis by Kim et al. demonstrated that immune checkpoint inhibitors therapy significantly improved OS in patients with KRAS-mutant NSCLC but not in those with the KRAS wild-type tumor [78]. The gene discussed is KRAS; the disease is neoplasm.